Literature DB >> 6271921

Prevalence of antibodies to Hepatitis A antigen in sera from patients with haematological malignancies.

E S McFarlane, J A Embil.   

Abstract

The prevalence of antibodies to hepatitis A (anti-HA) was investigated in patients attending a clinic for haematological malignancies. Patients were divided into three age groups; the number with antibodies in each group was recorded. Of the 130 patients studied, 44% of those aged 4-26, 70% of those aged 27-50, and 83% of those aged 51-76, were positive. This study identifies patients attending a clinic for haematological malignancies (ie, patients with immunologic deficiencies) as a group of people having a high prevalence of anti-HA. In the oldest group (51-76), urban patients had a higher prevalence than rural patients - a pattern similar to that observed in elderly Red Cross blood donors in a previous study. Seroconversion was noted in six patients, three of whom seroconverted from anti-HA-negative to anti HA-positive within 12 months of the initial visit to the clinic.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6271921     DOI: 10.1002/jmv.1890080104

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  4 in total

1.  Prevalence of antibodies to hepatitis A virus in Nova Scotia children.

Authors:  M D Crewe; J A Embil; J B Garner
Journal:  Can Med Assoc J       Date:  1983-05-15       Impact factor: 8.262

2.  Prevalence of antibody to hepatitis A virus in a Canadian Inuit community.

Authors:  G Y Minuk; J G Waggoner; R Jernigan; L E Nicolle; B Postl; J H Hoofnagle
Journal:  Can Med Assoc J       Date:  1982-11-01       Impact factor: 8.262

3.  Immunization of children receiving immunosuppressive therapy for cancer or hematopoietic stem cell transplantation.

Authors:  Avinash K Shetty; Mary A Winter
Journal:  Ochsner J       Date:  2012

Review 4.  Seroprevalence of hepatitis A infection in a low endemicity country: a systematic review.

Authors:  Ba' Pham; Bernard Duval; Gaston De Serres; Vladimir Gilca; Andrea C Tricco; Jan Ochnio; David W Scheifele
Journal:  BMC Infect Dis       Date:  2005-07-07       Impact factor: 3.090

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.